We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Merck KGaA Withdraws EU Application for MS Drug Movectro
Merck KGaA Withdraws EU Application for MS Drug Movectro
February 17, 2011
Merck KGaA has informed the European Medicines Agency (EMA) it is withdrawing its marketing authorization application for Movectro as an oral treatment for relapsing-remitting multiple sclerosis (MS) as its approval appeared doubtful.